Blue Jet Healthcare rises on commissioning production block at Ambernath Unit 2 facility
Blue Jet Healthcare is currently trading at Rs. 504.10, up by 1.70 points or 0.34% from its previous closing of Rs. 502.40 on the BSE.
The scrip opened at Rs. 510.00 and has touched a high and low of Rs. 517.95 and Rs. 503.00 respectively. So far 5954 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 578.00 on 19-Nov-2024 and a 52 week low of Rs. 319.40 on 12-Dec-2023.
Last one week high and low of the scrip stood at Rs. 517.95 and Rs. 494.00 respectively. The current market cap of the company is Rs. 8766.94 crore.
The promoters holding in the company stood at 86.00%, while Institutions and Non-Institutions held 3.92% and 10.07% respectively.
Blue Jet Healthcare has successfully completed commissioning of production block to manufacture Advance Contrast Media at its existing Unit 2 facility situated at Ambernath, Maharashtra. The company has commissioned production block on December 9, 2024. The total investment required is around Rs 10 crore.
Earlier, the company had successfully completed commissioning of multi- product Production block to manufacture pharma intermediates at its existing Unit 2 facility situated at Ambernath, Maharashtra, India.
The Mumbai-based Blue Jet Healthcare is a specialty pharmaceutical and healthcare ingredient and intermediate company, offering niche products targeted towards innovator pharmaceutical companies and multinational generic pharmaceutical companies.
